The Cholinergic Paradox: A Biphasic Shift in Alzheimer’s and Down Syndrome Memory
A study in mouse models of Alzheimer’s disease and Down syndrome challenges the long-held cholinergic hypothesis, which posits a uniform deficiency in cholinergic signaling. The research reveals a biphasic, time-dependent effect: early disease stages are characterized by cholinergic hyperactivity, which impairs memory, while late stages show the expected deficiency. In young model mice, anticholinergic treatments restored memory, whereas the acetylcholinesterase inhibitor donepezil improved memory only in older animals. This suggests that therapeutic strategies targeting the cholinergic system must be tailored to the specific stage of disease progression.
Why it might matter to you:
This finding underscores the critical importance of temporal context in neurodegenerative disease biomarkers and treatment. For your work in proteomic biomarkers, it highlights that a single molecular pathway can exhibit opposing functional states over time, which could confound diagnostic assays if not staged correctly. This reinforces the need to correlate fluid biomarkers with longitudinal clinical and imaging data to accurately interpret their clinical actionability and guide stage-specific therapeutic interventions.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
